» Articles » PMID: 32374857

Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2020 May 7
PMID 32374857
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Many substances for which consumer safety risk assessments need to be conducted are not associated with specific toxicity modes of action, but rather exhibit nonspecific toxicity leading to cell stress. In this work, a cellular stress panel is described, consisting of 36 biomarkers representing mitochondrial toxicity, cell stress, and cell health, measured predominantly using high content imaging. To evaluate the panel, data were generated for 13 substances at exposures consistent with typical use-case scenarios. These included some that have been shown to cause adverse effects in a proportion of exposed humans and have a toxicological mode-of-action associated with cellular stress (eg, doxorubicin, troglitazone, and diclofenac), and some that are not associated with adverse effects due to cellular stress at human-relevant exposures (eg, caffeine, niacinamide, and phenoxyethanol). For each substance, concentration response data were generated for each biomarker at 3 timepoints. A Bayesian model was then developed to quantify the evidence for a biological response, and if present, a credibility range for the estimated point of departure (PoD) was determined. PoDs were compared with the plasma Cmax associated with the typical substance exposures, and indicated a clear differentiation between "low" risk and "high" risk chemical exposure scenarios. Developing robust methods to characterize the in vitro bioactivity of xenobiotics is an important part of non-animal safety assessment. The results presented in this work show that the cellular stress panel can be used, together with other new approach methodologies, to identify chemical exposures that are protective of consumer health.

Citing Articles

Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety.

de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D Front Toxicol. 2025; 7:1426132.

PMID: 40061084 PMC: 11885506. DOI: 10.3389/ftox.2025.1426132.


Advancing systemic toxicity risk assessment: Evaluation of a NAM-based toolbox approach.

Cable S, Baltazar M, Bunglawala F, Carmichael P, Contreas L, Dent M Toxicol Sci. 2024; 204(1):79-95.

PMID: 39693112 PMC: 11879040. DOI: 10.1093/toxsci/kfae159.


Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!.

Lu E, Rusyn I, Chiu W J Toxicol Environ Health B Crit Rev. 2024; 28(1):28-62.

PMID: 39390665 PMC: 11614695. DOI: 10.1080/10937404.2024.2412571.


Next-generation risk assessment read-across case study: application of a 10-step framework to derive a safe concentration of daidzein in a body lotion.

Najjar A, Kuhnl J, Lange D, Genies C, Jacques C, Fabian E Front Pharmacol. 2024; 15:1421601.

PMID: 38962304 PMC: 11220827. DOI: 10.3389/fphar.2024.1421601.


Searching for LINCS to Stress: Using Text Mining to Automate Reference Chemical Curation.

Chambers B, Basili D, Word L, Baker N, Middleton A, Judson R Chem Res Toxicol. 2024; 37(6):878-893.

PMID: 38736322 PMC: 11447707. DOI: 10.1021/acs.chemrestox.3c00335.


References
1.
Trietsch S, Naumovska E, Kurek D, Setyawati M, Vormann M, Wilschut K . Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes. Nat Commun. 2017; 8(1):262. PMC: 5557798. DOI: 10.1038/s41467-017-00259-3. View

2.
Wang M, Kaufman R . Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016; 529(7586):326-35. DOI: 10.1038/nature17041. View

3.
OBrien P, Irwin W, Diaz D, Howard-Cofield E, Krejsa C, Slaughter M . High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006; 80(9):580-604. DOI: 10.1007/s00204-006-0091-3. View

4.
Watt E, Judson R . Uncertainty quantification in ToxCast high throughput screening. PLoS One. 2018; 13(7):e0196963. PMC: 6059398. DOI: 10.1371/journal.pone.0196963. View

5.
Plosker G, Faulds D . Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1999; 57(3):409-38. DOI: 10.2165/00003495-199957030-00014. View